# Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Source: https://onco.cc/trials/nct06311214/  
OnCo record `nct06311214` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An early trial studying the safety and activity of experimental treatment. Its registry status does not establish patient benefit.

## Summary

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial). ClinicalTrials.gov record last updated 2026-09-04: recruiting. Enrollment is planned at 500 participants. Primary completion is estimated at 2028-03-31. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Registry id: NCT06311214
- Phase: 2
- Setting: Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
- Sponsor: National Cancer Institute (NCI)

## Notes

- ClinicalTrials.gov record last updated 2026-09-04: recruiting. Enrollment is planned at 500 participants. Primary completion is estimated at 2028-03-31. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT06311214: https://clinicaltrials.gov/study/NCT06311214

## Connected records

- targets: [TROP2](https://onco.cc/targets/trop2/)

---
JSON: https://onco.cc/api/v1/entities/nct06311214.json